ArticleInflammatory intestinal diseases

An Early Phase 2 Double-Blind, Placebo-Controlled Study of E6011, a Novel Anti-Fractalkine Antibody, in Patients with Crohn's Disease.

Taku Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.